| Primary information |
|---|
| sequence ID | Seq_8355 |
| Peptide sequence | TLEIPGNSDPNMIPDGDFNS |
| CancerPDF_ID | CancerPDF_ID875, CancerPDF_ID9306, |
| PMID | 19795908,24694173 |
| Protein Name | Complement C4-B,Complement C4-A |
| UniprotKB Entry Name | CO4B_HUMAN,CO4A_HUMAN |
| Fluid | Plasma,Ascites fluid |
| M/Z | 1066.97,NA |
| Charge | 2,1 |
| Mass (in Da) | NA,NA |
| fdr | NA,NA |
| Profiling Technique | LC-MS,LTQ-Orbitrap XL |
| Peptide Identification technique | MALDI-TOF/TOF,X tandem for peptide identification |
| Quantification Technique | LC-MRM (multiple reaction monitoring),NA |
| Labelled/Label Free | Labelled,Label Free |
| FDR | less than 7%,NA |
| CancerPDF_ID | CancerPDF_ID875, CancerPDF_ID9306, |
| p-Value | NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,"X tandem for peptide identification,Scaffold 2 software for any modification analysis" |
| Length | 20,20 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Ovarian cancer |
| Database | NCBI refseq Protein Database,"IPI00032258,IPI00418163,IPI00643525,IPI00654875,IPI00843913,IPI00887154,IPI00889723,IPI00892547,IPI00892604,IPI00937598" |
| Modification | NA,NA |
| Number of Patients | "42 normal, 28 patients",3 ovarian cancer patient and 3 non cancerous control |
| Regulation | NA,Uniquely expressed in ovarian cancer patient |
| Validation | NA,NA |
| Sensitivity | NA,NA |
| Specificity | NA,NA |
| Accuracy | NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |